Page last updated: 2024-11-05

pirinixic acid and Osteoarthritis

pirinixic acid has been researched along with Osteoarthritis in 3 studies

pirinixic acid: structure

Osteoarthritis: A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.

Research Excerpts

ExcerptRelevanceReference
"To characterize the inhibitory effects of therapeutic concentrations of the nonsteroidal antiinflammatory drug nimesulide (NIM) on peroxisome proliferator-activated receptor (PPAR)-induced cyclooxygenase 2 (COX-2) gene expression in human synovial fibroblasts (HSFs) from patients with osteoarthritis (OA) and to define the intracellular mechanisms mediating the response."3.71Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism. ( Di Battista, JA; Fahmi, H; Faour, WH; He, QW; Kalajdzic, T; Martel-Pelletier, J; Pelletier, JP, 2002)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhou, Y1
Chen, X1
Qu, N1
Zhang, B1
Xia, C1
Huang, D1
Zhao, Q1
Liu, H1
Guo, Y1
Xu, H1
Kalajdzic, T1
Faour, WH1
He, QW1
Fahmi, H1
Martel-Pelletier, J1
Pelletier, JP1
Di Battista, JA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396]Phase 2701 participants (Actual)Interventional2020-08-18Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

All-Cause Death

Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days

InterventionParticipants (Count of Participants)
Fenofibrate + Usual Care19
Placebo + Usual Care22

Exploratory Hierarchical Composite Endpoint

The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days

Interventionscore on a scale (Median)
Fenofibrate + Usual Care5.03
Placebo + Usual Care5.03

Number of Days Alive and Out of the Hospital During the 30 Days Following Randomization

Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days

Interventiondays (Median)
Fenofibrate + Usual Care30
Placebo + Usual Care30

Number of Days Alive, Out of the Intensive Care Unit, Free of Mechanical Ventilation/Extracorporeal Membrane Oxygenation, or Maximal Available Respiratory Support in the 30 Days Following Randomization

Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days

Interventiondays (Mean)
Fenofibrate + Usual Care28.8
Placebo + Usual Care28.3

Primary Hierarchical Composite Endpoint

The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days

InterventionRanked Severity Score (Median)
Fenofibrate + Usual Care5.32
Placebo + Usual Care5.33

Secondary Hierarchical Composite Endpoint

The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days

Interventionscore on a scale (Median)
Fenofibrate + Usual Care5.05
Placebo + Usual Care5.05

Seven-category Ordinal Scale

A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days

Interventionscore on a scale (Median)
Fenofibrate + Usual Care1
Placebo + Usual Care1

Other Studies

3 other studies available for pirinixic acid and Osteoarthritis

ArticleYear
Chondroprotection of PPARα activation by WY14643 via autophagy involving Akt and ERK in LPS-treated mouse chondrocytes and osteoarthritis model.
    Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:4

    Topics: Animals; Anticholesteremic Agents; Autophagy; Cartilage, Articular; Chondrocytes; Disease Models, An

2019
PPAR-α Agonist WY-14643 Inhibits LPS-Induced Inflammation in Synovial Fibroblasts via NF-kB Pathway.
    Journal of molecular neuroscience : MN, 2016, Volume: 59, Issue:4

    Topics: Anti-Inflammatory Agents; Cells, Cultured; Chemokine CCL2; Dinoprostone; Endothelin-1; Fibroblasts;

2016
Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism.
    Arthritis and rheumatism, 2002, Volume: 46, Issue:2

    Topics: Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; DNA-Bindi

2002